Fasinumab
Fasinumab is a human monoclonal antibody designed for the treatment of acute sciatic pain.[1][2]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | HNGF |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6406H9896N1700O2026S46 |
| Molar mass | 144618.27 g·mol−1 |
This drug was developed in collaboration by Teva Pharmaceutical Industries and Regeneron Pharmaceuticals.
It is currently at Phase III trials.
See also
References
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Bone ("-os-", "-s(o)-") |
| ||||||||
| Musculoskeletal ("-mul-") |
| ||||||||
| Circulatory ("-c(i[r])-") |
| ||||||||
| Neurologic ("-ne(u)(r)-") |
| ||||||||
| Angiogenesis inhibitor ("-anibi-") |
| ||||||||
| Growth factor ("-gr(o)-") |
| ||||||||
| |||||||||
| Angiopoietin |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CNTF | |||||||||||
| EGF (ErbB) |
| ||||||||||
| FGF |
| ||||||||||
| HGF (c-Met) |
| ||||||||||
| IGF |
| ||||||||||
| LNGF (p75NTR) |
| ||||||||||
| PDGF |
| ||||||||||
| RET (GFL) |
| ||||||||||
| SCF (c-Kit) | |||||||||||
| TGFβ |
| ||||||||||
| Trk |
| ||||||||||
| VEGF |
| ||||||||||
| Others |
| ||||||||||
| |||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.